23andMe independent board resigns in feud over CEO Anne Wojcicki’s plan to take company private
All seven of 23andMe’s independent board members resigned in a stinging rebuke to a proposal by CEO Anne Wojcicki’s plans to to take the company private. Wojcicki, who has been trying to take the company private since April, proposed to acquire all outstanding shares of 23andMe not owned by her or her affiliates for $0.40 per share, in July.
Led by CEO Wojcicki, 23andMe gives users insights into ... And in July, GlaxoSmithKline became 23andMe’s latest pharma partner, leveraging users’ anonymous genetic data to develop drugs.
2don MSNIn Depth
That’s especially true in tech, where names become verbs, and the same logic applies to companies, firms, and strategies—and ...
Co-Founder and CEO Anne Wojcicki has failed to offer an actionable ... with advisers and intended to begin speaking to potential partners and financing sources, the filing said.
Investors have sent stocks and bonds higher on expectations of a soft landing. But some Republicans think the central bank ...
A proposal by 23andMe founder and chief executive Anne Wojcicki to take the genetic testing ... Today, it was named as a partner in a research consortium in the US set up to build an open-source ...
In the U.S. in the early 1960s the distributor of a thalidomide drug was impatient to get it on the market. But FDA medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback